Cas:138614-30-9 Icatibant acetate manufacturer & supplier

We serve Chemical Name:Icatibant acetate CAS:138614-30-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Icatibant acetate

Chemical Name:Icatibant acetate
CAS.NO:138614-30-9
Synonyms:Icatibant acetate
Molecular Formula:C61H93N19O15S
Molecular Weight:1364.57000
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.6g/cm3
Index of Refraction:
PSA:581.76000
Exact Mass:1363.68000
LogP:1.67610

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like Icatibant acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Icatibant acetate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Icatibant acetate Use and application,Icatibant acetate technical grade,usp/ep/jp grade.


Related News: Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. Icatibant acetate manufacturer However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial. Icatibant acetate supplier Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. Icatibant acetate vendor However, the study did not produce any significant benefits when it came to thinking, reasoning and memory tests performed across the entire patient group — possibly because there were too few people with clinically diagnosed Alzheimer’s participating in the trial. Icatibant acetate factory Analysts at Mizuho Americas, who spoke to Lilly’s management this week, said that may well have now changed. “Overall, it sounds like the approval raises new questions for Lilly (as it does for many of us!),” the firm said in a note to clients.